Dr. Krishnan Viswanadhan joined Agios as Chief Corporate Development and Strategy Officer in March 2025. He is a seasoned biopharmaceutical executive with over 20 years of cross-functional experience in advancing novel medicines for patients with serious and life-threatening diseases.
Prior to joining Agios, Krishnan served as President and Chief Operating Officer at Be Biopharma, where he led all operational aspects of the company. Before that, he was Senior Vice President, Global Cell Therapy Franchise Lead at Bristol Myers Squibb, where he oversaw the integrated cell therapy franchise strategy across the enterprise. In this role, he spearheaded key investments to drive long-term growth and built core capabilities to support the company’s leadership in cell therapy. He also led the teams responsible for the development, approval, and life cycle management of Breyanzi, a CD19 CAR-T therapy, and Abecma, the first BCMA CAR-T therapy. Earlier in his career, Krishnan was Vice President, Business Development and Global Alliances at Celgene Corporation, managing a portfolio of strategic partnerships and equity investments. Before Celgene, he held various roles in regulatory strategy at both large and small biopharmaceutical companies.
Krishnan is a registered pharmacist with a Doctor of Pharmacy degree from Rutgers University and a Master of Business Administration from Cornell University. He currently serves as a non-executive director on the boards of JW Therapeutics, a leading cell therapy company in China and Cargo Therapeutics, a clinical-stage biotechnology company advancing next generation, potentially curative cell therapies for cancer patients.
What is Krishnan Viswanadhan's net worth?
The estimated net worth of Krishnan Viswanadhan is at least $142.98 thousand as of March 5th, 2026. Dr. Viswanadhan owns 5,141 shares of Agios Pharmaceuticals stock worth more than $142,981 as of March 13th. This net worth approximation does not reflect any other assets that Dr. Viswanadhan may own. Learn More about Krishnan Viswanadhan's net worth.
How do I contact Krishnan Viswanadhan?
Has Krishnan Viswanadhan been buying or selling shares of Agios Pharmaceuticals?
During the past quarter, Krishnan Viswanadhan has sold $82,260.20 in shares of Agios Pharmaceuticals stock. Most recently, Krishnan Viswanadhan sold 2,959 shares of the business's stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $27.80, for a transaction totalling $82,260.20. Following the completion of the sale, the insider now directly owns 5,141 shares of the company's stock, valued at $142,919.80. Learn More on Krishnan Viswanadhan's trading history.
Who are Agios Pharmaceuticals' active insiders?
Agios Pharmaceuticals' insider roster includes Carman Alenson (Insider), Jonathan Biller (CFO & Head of Corp. Affairs ), Christopher Bowden (Insider), James Burns (https://www.linkedin.com/in/jackie-fouse-a90b811aa), Jacqualyn Fouse (CEO & Director ), Jacqualyn Fouse (Director), Sarah Gheuens (Chief Medical Officer, Head of R&D), Brian Goff (CEO), Cecilia Jones (CFO), Tsveta Milanova (Chief Commercial Officer), Darrin Miles (Insider), David Scadden (Director), and Krishnan Viswanadhan (Insider). Learn More on Agios Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Agios Pharmaceuticals?
In the last year, insiders at the biopharmaceutical company sold shares 23 times. They sold a total of 117,306 shares worth more than $3,824,642.46. The most recent insider tranaction occured on March, 5th when insider Krishnan Viswanadhan sold 2,959 shares worth more than $82,260.20. Insiders at Agios Pharmaceuticals own 4.3% of the company.
Learn More about insider trades at Agios Pharmaceuticals. Information on this page was last updated on 3/5/2026.
